Evidence map›Paper›PMID 29549388›Full record

ArticleKnee surgery, sports traumatology, arthroscopy : official journal of the ESSKA2018

The safety and efficacy of magnetic targeting using autologous mesenchymal stem cells for cartilage repair.

Naosuke Kamei, Mitsuo Ochi, Nobuo Adachi, Masakazu Ishikawa, Shinobu Yanada, L Scott Levin, Goki Kamei, Takaaki Kobayashi

Abstract read
PubMed Publisher
In one paragraph

Article in Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 1 pooled it
5.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 1 synthesis or guideline pooled it, 54 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Mesenchymal Stem Cells for Neurological Disorders.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2021
    Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 3 countries.

Naosuke KameiDepartment of Orthopaedic Surgery, Division of Medicine, Biomedical Sciences Major, Graduate School of Biomedical Science, Hiroshima University, Hiroshima, Japan.
Mitsuo OchiHiroshima University, Higashihiroshima, Japan. ochim@hiroshima-u.ac.jp.ORCID http://orcid.org/0000-0002-7363-873X
Nobuo AdachiDepartment of Orthopaedic Surgery, Division of Medicine, Biomedical Sciences Major, Graduate School of Biomedical Science, Hiroshima University, Hiroshima, Japan.
Masakazu IshikawaDepartment of Orthopaedic Surgery, Division of Medicine, Biomedical Sciences Major, Graduate School of Biomedical Science, Hiroshima University, Hiroshima, Japan.
Shinobu YanadaJapan Tissue Engineering Co. Ltd, Gamagori, Japan.
L Scott LevinDepartment of Orthopaedic Surgery, University of Pennsylvania, Philadelphia, PA, USA.
Goki KameiDepartment of Orthopaedic Surgery, Hiroshima Prefectural Hospital, Hiroshima, Japan.
Takaaki KobayashiDepartment of Orthopaedic Surgery, Tsuchiya General Hospital, Hiroshima, Japan.
Hiroshima University · JPHiroshima General Hospital · JPHiroshima Prefectural Hospital · JPTissue Dynamics (Israel) · ILUniversity of Pennsylvania · US

Funding

Japan Agency for Medical Research and Development 16bk0104020h0003
6 · The paper itself

Abstract

purposeA new cell delivery system using magnetic force, termed magnetic targeting, was developed for the accumulation of locally injected cells in a lesion. The aim of this study was to assess the safety and efficacy of mesenchymal stem cell (MSC) magnetic targeting in patients with a focal articular cartilage defect in the knee.

methodsMSC magnetic targeting for five patients was approved by the Ministry of Health Labour and Welfare of Japan. Autologous bone marrow MSCs were cultured and subsequently magnetized with ferucarbotran. The 1.0-T compact magnet was attached to a suitable position around the knee joint to allow the magnetic force to be as perpendicular to the surface of the lesion as possible. Then 1 × 10

resultsNo serious adverse events were observed during the treatment or in the follow-up period. Swelling of the treated knee joint was observed from the day after surgery in three of the five patients. The swelling resolved within 2 weeks in two patients. MRI showed that the cartilage defect areas were almost completely filled with cartilage-like tissue. MOCART scores were significantly higher 48 weeks postoperatively than preoperatively (74.8 ± 10.8 vs 27.0 ± 16.8, p = 0.042). Arthroscopy in three patients showed complete coverage of their cartilage defects. Clinical outcome scores were significantly better 48 weeks postoperatively than preoperatively for the IKDC Subjective Knee Evaluation (74.8 ± 17.7 vs 46.9 ± 17.7, p = 0.014) and knee-related quality-of-life (QOL) in the KOOS (53.8 ± 26.4 vs 22.5 ± 30.8, p = 0.012).

conclusionMagnetic targeting of MSCs was safely performed and showed complete coverage of the defects with cartilage-like tissues and significant improvement in clinical outcomes 48 weeks after treatment. The magnetic targeting of MSCs is useful as a minimally invasive treatment for cartilage repair. LEVEL OF EVIDENCE: IV.

Indexed as

DextransMagnetite NanoparticlesMesenchymal Stem Cell TransplantationAdolescentAdultAgedCartilage, ArticularFemaleHumansKnee InjuriesMagnetic Resonance ImagingMaleMiddle AgedTransplantation, AutologousYoung AdultDextransferumoxidesMagnetite NanoparticlesCartilage regenerationCell transplantationClinical outcomeMagnetMesenchymal stem cell

Identifiers

PMID29549388
OpenAlexW2792355710

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.